Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365207 · ClinicalTrials.gov registry record · NA
Intravesical BCG Administration to Patients With Invasive Bladder Cancer
A NA study, sponsored by The University of Texas Health Science Center at San Antonio.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02365207: Clinical Trial NA study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT02365207 is a NA study that was terminated before completion, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02365207, a NA study, was terminated before completion, sponsored by The University of Texas Health Science Center at San Antonio.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.
Primary Outcome
The tumor specific immunity is measured by the change in T cell proliferation post-treatment compared to the pre-treatment assessment, which will require a sample size of at least 10
Interventions
- DRUG BCG strain of Mycobacterium bovis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-11 |
| Est. Completion | 2019-04-25 |
| Phase | NA |
Why NCT02365207 stopped before completion
NCT02365207 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which BCG strain of Mycobacterium bovis is the first listed.
NCT02365207 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02365207 about?
NCT02365207 is a clinical study titled "Intravesical BCG Administration to Patients With Invasive Bladder Cancer". Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.
What is the current status of trial NCT02365207?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2013-11. Estimated completion is 2019-04-25.
What interventions are being tested in trial NCT02365207?
The interventions under investigation include: BCG strain of Mycobacterium bovis (DRUG).
Who is sponsoring clinical trial NCT02365207?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02365207's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia